AP3329A - Acylated glucagon analogues - Google Patents
Acylated glucagon analoguesInfo
- Publication number
- AP3329A AP3329A AP2012006107A AP2012006107A AP3329A AP 3329 A AP3329 A AP 3329A AP 2012006107 A AP2012006107 A AP 2012006107A AP 2012006107 A AP2012006107 A AP 2012006107A AP 3329 A AP3329 A AP 3329A
- Authority
- AP
- ARIPO
- Prior art keywords
- glucagon analogues
- acylated glucagon
- acylated
- analogues
- glucagon
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22508009P | 2009-07-13 | 2009-07-13 | |
| EP09251780 | 2009-07-13 | ||
| EP10157240 | 2010-03-22 | ||
| DKPA201000412 | 2010-05-10 | ||
| PCT/DK2010/000099 WO2011006497A1 (en) | 2009-07-13 | 2010-06-24 | Acylated glucagon analogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2012006107A0 AP2012006107A0 (en) | 2012-02-29 |
| AP3329A true AP3329A (en) | 2015-06-30 |
Family
ID=43448959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2012006107A AP3329A (en) | 2009-07-13 | 2010-06-24 | Acylated glucagon analogues |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US9156901B2 (ko) |
| EP (1) | EP2454282B1 (ko) |
| JP (1) | JP6054742B2 (ko) |
| KR (1) | KR101809024B1 (ko) |
| CN (2) | CN104961822A (ko) |
| AP (1) | AP3329A (ko) |
| AU (1) | AU2010272944B2 (ko) |
| CA (1) | CA2767792A1 (ko) |
| DK (1) | DK2454282T3 (ko) |
| EA (1) | EA022816B1 (ko) |
| EC (1) | ECSP12011593A (ko) |
| ES (1) | ES2537287T3 (ko) |
| GE (1) | GEP20146056B (ko) |
| HR (1) | HRP20150557T1 (ko) |
| HU (1) | HUE026255T2 (ko) |
| IL (1) | IL217150A0 (ko) |
| MA (1) | MA33517B1 (ko) |
| ME (1) | ME02220B (ko) |
| MX (1) | MX2012000564A (ko) |
| MY (1) | MY188182A (ko) |
| NZ (1) | NZ597981A (ko) |
| PE (1) | PE20121130A1 (ko) |
| PL (1) | PL2454282T3 (ko) |
| PT (1) | PT2454282E (ko) |
| RS (1) | RS53987B1 (ko) |
| SG (1) | SG177609A1 (ko) |
| SI (1) | SI2454282T1 (ko) |
| UA (1) | UA104766C2 (ko) |
| WO (1) | WO2011006497A1 (ko) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110126592A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| WO2010070255A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| PH12012502472A1 (en) | 2010-06-24 | 2013-03-25 | Zealand Pharma As | Glucagon analogues |
| KR20140043709A (ko) * | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| WO2012153196A2 (en) | 2011-05-10 | 2012-11-15 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| PE20240686A1 (es) | 2011-06-10 | 2024-04-10 | Hanmi Science Co Ltd | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) |
| PE20230404A1 (es) * | 2011-06-17 | 2023-03-07 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
| RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
| WO2013092703A2 (en) * | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| EP2664374A1 (en) * | 2012-05-15 | 2013-11-20 | F. Hoffmann-La Roche AG | Lysin-glutamic acid dipeptide derivatives |
| KR20150023690A (ko) | 2012-06-14 | 2015-03-05 | 사노피 | 엑센딘-4 펩타이드 유사체 |
| AU2013295035B2 (en) * | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PE20151421A1 (es) | 2012-11-06 | 2015-09-24 | Hanmi Pharm Ind Co Ltd | Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| AU2014230472A1 (en) * | 2013-03-14 | 2015-10-01 | Medimmune Limited | Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity |
| WO2014147129A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| CN105189465B (zh) | 2013-03-21 | 2019-02-26 | 赛诺菲-安万特德国有限公司 | 合成含有乙内酰脲的肽产物 |
| WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
| SI2986313T1 (sl) | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| WO2015055801A1 (en) | 2013-10-17 | 2015-04-23 | Zealand Pharma A/S | Acylated glucagon analogues |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080155A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| WO2015124612A1 (en) * | 2014-02-18 | 2015-08-27 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| CN117180445A (zh) | 2014-05-28 | 2023-12-08 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CN106519015B (zh) | 2014-09-23 | 2020-04-17 | 深圳市图微安创科技开发有限公司 | 胃泌酸调节素类似物 |
| US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| MY185334A (en) | 2014-12-30 | 2021-05-06 | Hanmi Pharm Ind Co Ltd | Glucagon derivatives with improved stability |
| EA034820B1 (ru) | 2015-02-17 | 2020-03-25 | Эли Лилли Энд Компани | Порошковый состав для интраназального введения для лечения гипогликемии |
| AR103954A1 (es) | 2015-03-18 | 2017-06-14 | Zealand Pharma As | Análogos de amilina |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| EA201890058A1 (ru) | 2015-06-30 | 2018-07-31 | Ханми Фарм. Ко., Лтд. | Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017116204A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
| AR107890A1 (es) | 2016-03-10 | 2018-06-28 | Medimmune Ltd | Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad |
| CN106084031B (zh) * | 2016-06-02 | 2020-03-31 | 中国药科大学 | 一类glp-1r/gcgr双重激动剂在用于降糖和减肥药物中的运用 |
| CN105968186B (zh) * | 2016-06-02 | 2020-10-30 | 中国药科大学 | 具有长效化作用的胰高血糖素(Glu)类似物及其应用 |
| EP3468569A4 (en) * | 2016-06-09 | 2020-05-27 | AmideBio LLC | GLUCAGON ANALOG AND METHOD FOR USE THEREOF |
| KR102005457B1 (ko) | 2016-06-29 | 2019-07-30 | 한미약품 주식회사 | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 |
| US9994591B2 (en) | 2016-08-05 | 2018-06-12 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
| AU2017371516C1 (en) * | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| JP2020500890A (ja) * | 2016-12-09 | 2020-01-16 | ジーランド・ファーマ・ア／エス | Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| WO2019149657A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| AU2019215709A1 (en) | 2018-02-02 | 2020-07-16 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| CN110317258B (zh) * | 2018-03-29 | 2023-03-17 | 齐鲁制药有限公司 | 一种索玛鲁肽的新多肽片段及其制备方法 |
| US11780900B2 (en) | 2018-04-25 | 2023-10-10 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
| KR20210109552A (ko) | 2018-12-21 | 2021-09-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 이중특이적 단백질 |
| TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| EP4058047A1 (en) | 2019-11-11 | 2022-09-21 | Boehringer Ingelheim International GmbH | Npy2 receptor agonists |
| AU2020397917A1 (en) | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| DK4153599T3 (da) | 2020-05-22 | 2024-06-17 | Boehringer Ingelheim Int | Fremgangsmåde til at fremstille alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-carboxylat |
| ES2991340T3 (es) | 2020-05-22 | 2024-12-03 | Boehringer Ingelheim Int | Procedimiento continuo de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| MX2023014771A (es) | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101017A2 (en) * | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2010070251A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| WO1998011126A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1999025727A2 (en) | 1997-11-14 | 1999-05-27 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| DE69922043T2 (de) | 1998-12-07 | 2005-11-24 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Glp-1 analoge |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| ATE424413T1 (de) | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| PL374949A1 (en) | 2001-12-20 | 2005-11-14 | Eli Lilly And Company | Insulin molecule having protracted time action |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US20060217290A1 (en) | 2003-04-29 | 2006-09-28 | Kohn Wayne D | Insulin analogs having protracted time action |
| RU2413530C9 (ru) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP1883419A4 (en) | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| RU2485135C2 (ru) | 2005-06-13 | 2013-06-20 | Импиэриэл Инноувейшнс Лимитид | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) |
| WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| EP2570133B1 (en) | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| EP2074140B8 (en) | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| CN102007143B (zh) | 2008-01-09 | 2015-08-26 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的新型胰岛素衍生物 |
| EP2229406B1 (de) | 2008-01-09 | 2015-04-22 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| RU2010147076A (ru) | 2008-04-22 | 2012-05-27 | Кейз Вестерн Ризев Юнивесити (Us) | Аналоги инсулина специфичные к изоформам |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| CA2732439A1 (en) | 2008-07-31 | 2010-02-04 | Case Western Reserve University | Halogen-stabilized insulin |
| KR101417873B1 (ko) | 2008-08-07 | 2014-07-09 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체 |
| US8637647B2 (en) | 2008-09-12 | 2014-01-28 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| WO2010070255A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| KR20110126592A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| WO2010080609A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010080606A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Insulin analogs |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| WO2010107487A2 (en) | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| BR112012018104A2 (pt) | 2010-01-20 | 2017-10-17 | Zeland Pharma As | tratamento de doenças cardíacas |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| EP2552952A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| BR112012027545B1 (pt) | 2010-04-27 | 2020-09-24 | Betta Pharmaceuticals Co., Ltd. | Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| PH12012502472A1 (en) | 2010-06-24 | 2013-03-25 | Zealand Pharma As | Glucagon analogues |
| EP2637698B1 (en) | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| KR20140043709A (ko) | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| JP2014510739A (ja) | 2011-03-28 | 2014-05-01 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| RU2602601C2 (ru) | 2011-04-12 | 2016-11-20 | Ново Нордиск А/С | Дважды ацилированные производные glp-1 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| WO2012153196A2 (en) | 2011-05-10 | 2012-11-15 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
| WO2013092703A2 (en) | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| AU2013295035B2 (en) | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2015055801A1 (en) | 2013-10-17 | 2015-04-23 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| WO2015124612A1 (en) | 2014-02-18 | 2015-08-27 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
-
2010
- 2010-06-24 AP AP2012006107A patent/AP3329A/xx active
- 2010-06-24 ME MEP-2015-72A patent/ME02220B/me unknown
- 2010-06-24 KR KR1020127003479A patent/KR101809024B1/ko not_active Expired - Fee Related
- 2010-06-24 DK DK10737252T patent/DK2454282T3/en active
- 2010-06-24 PT PT107372526T patent/PT2454282E/pt unknown
- 2010-06-24 NZ NZ597981A patent/NZ597981A/en not_active IP Right Cessation
- 2010-06-24 PL PL10737252T patent/PL2454282T3/pl unknown
- 2010-06-24 CN CN201510319285.XA patent/CN104961822A/zh active Pending
- 2010-06-24 SG SG2012002010A patent/SG177609A1/en unknown
- 2010-06-24 SI SI201030922T patent/SI2454282T1/sl unknown
- 2010-06-24 HU HUE10737252A patent/HUE026255T2/en unknown
- 2010-06-24 GE GEAP201012567A patent/GEP20146056B/en unknown
- 2010-06-24 EP EP10737252.6A patent/EP2454282B1/en active Active
- 2010-06-24 HR HRP20150557TT patent/HRP20150557T1/hr unknown
- 2010-06-24 AU AU2010272944A patent/AU2010272944B2/en not_active Ceased
- 2010-06-24 RS RS20150326A patent/RS53987B1/sr unknown
- 2010-06-24 WO PCT/DK2010/000099 patent/WO2011006497A1/en not_active Ceased
- 2010-06-24 CA CA2767792A patent/CA2767792A1/en not_active Abandoned
- 2010-06-24 CN CN201080038110.7A patent/CN102574903B/zh not_active Expired - Fee Related
- 2010-06-24 MY MYPI2012000113A patent/MY188182A/en unknown
- 2010-06-24 JP JP2012519884A patent/JP6054742B2/ja not_active Expired - Fee Related
- 2010-06-24 US US13/383,783 patent/US9156901B2/en not_active Expired - Fee Related
- 2010-06-24 ES ES10737252.6T patent/ES2537287T3/es active Active
- 2010-06-24 MX MX2012000564A patent/MX2012000564A/es active IP Right Grant
- 2010-06-24 UA UAA201201419A patent/UA104766C2/uk unknown
- 2010-06-24 PE PE2012000038A patent/PE20121130A1/es not_active Application Discontinuation
- 2010-06-24 EA EA201290027A patent/EA022816B1/ru not_active IP Right Cessation
-
2011
- 2011-12-22 IL IL217150A patent/IL217150A0/en unknown
-
2012
- 2012-01-11 EC EC2012011593A patent/ECSP12011593A/es unknown
- 2012-02-08 MA MA34615A patent/MA33517B1/fr unknown
-
2015
- 2015-09-02 US US14/843,047 patent/US10004786B2/en not_active Expired - Fee Related
-
2018
- 2018-05-22 US US15/985,934 patent/US20190076506A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101017A2 (en) * | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2010070251A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3329A (en) | Acylated glucagon analogues | |
| AP3286A (en) | Glucagon analogues | |
| ZA201104592B (en) | Glucagon analogues | |
| ZA201104593B (en) | Glucagon analogues | |
| IL213480A0 (en) | Glucagon analogues | |
| IL213477A0 (en) | Glucagon analogues | |
| AP2013006671A0 (en) | Glucagon analogues | |
| ZA201206838B (en) | Novel glucagon analogues | |
| EP2443235A4 (en) | ß-glucosidase VARIANTS | |
| ZA201201259B (en) | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | |
| GB0920846D0 (en) | Defenin inducing agent | |
| TWM372017U (en) | USB structure | |
| GB0920831D0 (en) | Clock | |
| GB2468933B (en) | Mechanical handless-faceless clock | |
| GB2468953B (en) | Freeze-cast components | |
| TWM373647U (en) | Insect-trapping structure | |
| GB0920959D0 (en) | ERoof structure | |
| TWM371434U (en) | Sun-hat structure | |
| TWM386189U (en) | Hanging-painting structure | |
| ZA201008616B (en) | Structure | |
| TWM371036U (en) | Doll-placing structure | |
| GB0711673D0 (en) | Glucagon analogues | |
| GB0903360D0 (en) | Concept seven | |
| GB0910058D0 (en) | Aerojection (ii) | |
| TWM365648U (en) | Candy structure |